公司概况
愿景与使命
管理团队
董事会
环境、社会和公司治理 (ESG)
联系我们
主要产品及管线
药物研发
生产基地
合作伙伴
新闻发布
媒体报道
奖项
演示文稿和会议直播
公告及通告
财务报告和上市文件
分析师覆盖
公司治理
活动日历
联系及邮件订阅
在招职位
云顶新耀宣布其授权合作伙伴Immunomedics新药Trodelvy (sacituzumab govitecan-hziy)获得美国食品药物管理局加速上市批准,用于既往治疗无效的转移性三阴性乳腺癌患者
云顶新耀宣布中国国家药品监督管理局批准sacituzumab govitecan临床试验申请, 将启动治疗转移性三阴性乳腺癌中国注册临床研究
云顶新耀宣布用于治疗复杂性腹腔内感染抗菌药物Xerava™获得新加坡卫生科学局批准
云顶新耀宣布其 taniborbactam (VNRX-5133)联合头孢吡肟体外研究取得积极成果
云顶新耀与嘉善国家级经济技术开发区和嘉善国投达成战略合作
Everest Medicines任命医学博士Kerry Blanchard出任董事兼首席执行官
Everest Medicines Announces Approval of Nefecon's Clinical Trial Application by the China National Medical Products Administration
Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia
Everest Medicines Expands Senior Leadership Team
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore
Everest Medicines Appoints Wende Chen as Chief Commercial Officer
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
Tetraphase Pharmaceuticals Announces FDA Approval of XERAVA™ (Eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
Everest Medicines Subsidiary Acquires Exclusive Worldwide License to Develop and Commercialize Clinical Stage Novel FGFR4 Kinase Inhibitor
Ian Woo Joins Everest Medicines as President and Chief Financial Officer; Named Managing Director of C-Bridge Capital
Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Admin
Tetraphase Pharmaceuticals Enters Into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China.
Arena eligible to receive up to $224M, including upfront and milestone payments, in addition to royalties.
C-Bridge Capital specializes in the growing Chinese health care market and is using its expertise to identify emerging industry leaders and bring global innovation into China.